Shenzhen Neptunus Bioengineering Co Ltd

SHE:000078 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.17 Billion
CN¥8.55 Billion CNY
Market Cap Rank
#9286 Global
#1886 in China
Share Price
CN¥3.25
Change (1 day)
-1.22%
52-Week Range
CN¥2.22 - CN¥5.29
All Time High
CN¥9.81
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and othe… Read more

Shenzhen Neptunus Bioengineering Co Ltd (000078) - Net Assets

Latest net assets as of September 2025: CN¥2.85 Billion CNY

Based on the latest financial reports, Shenzhen Neptunus Bioengineering Co Ltd (000078) has net assets worth CN¥2.85 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥27.28 Billion) and total liabilities (CN¥24.43 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥2.85 Billion
% of Total Assets 10.43%
Annual Growth Rate 14.78%
5-Year Change -62.03%
10-Year Change 32.7%
Growth Volatility 140.26

Shenzhen Neptunus Bioengineering Co Ltd - Net Assets Trend (1995–2024)

This chart illustrates how Shenzhen Neptunus Bioengineering Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Shenzhen Neptunus Bioengineering Co Ltd (1995–2024)

The table below shows the annual net assets of Shenzhen Neptunus Bioengineering Co Ltd from 1995 to 2024.

Year Net Assets Change
2024-12-31 CN¥2.84 Billion -32.57%
2023-12-31 CN¥4.22 Billion -30.98%
2022-12-31 CN¥6.11 Billion -16.39%
2021-12-31 CN¥7.31 Billion -2.42%
2020-12-31 CN¥7.49 Billion -4.60%
2019-12-31 CN¥7.85 Billion +9.67%
2018-12-31 CN¥7.16 Billion +10.64%
2017-12-31 CN¥6.47 Billion +10.07%
2016-12-31 CN¥5.88 Billion +174.28%
2015-12-31 CN¥2.14 Billion +20.22%
2014-12-31 CN¥1.78 Billion -5.58%
2013-12-31 CN¥1.89 Billion +78.62%
2012-12-31 CN¥1.06 Billion +8.85%
2011-12-31 CN¥971.04 Million +7.58%
2010-12-31 CN¥902.62 Million +30.33%
2009-12-31 CN¥692.59 Million -11.30%
2008-12-31 CN¥780.79 Million -13.59%
2007-12-31 CN¥903.62 Million +4.01%
2006-12-31 CN¥868.76 Million +7.89%
2005-12-31 CN¥805.26 Million -44.54%
2004-12-31 CN¥1.45 Billion +0.59%
2003-12-31 CN¥1.44 Billion -30.04%
2002-12-31 CN¥2.06 Billion +4.48%
2001-12-31 CN¥1.97 Billion +727.14%
2000-12-31 CN¥238.75 Million +16.07%
1999-12-31 CN¥205.69 Million +16.16%
1998-12-31 CN¥177.08 Million +207.28%
1997-12-31 CN¥57.63 Million +2.64%
1996-12-31 CN¥56.14 Million +7.65%
1995-12-31 CN¥52.15 Million --

Equity Component Analysis

This analysis shows how different components contribute to Shenzhen Neptunus Bioengineering Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 292403177000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock CN¥2.63 Billion 146.56%
Other Comprehensive Income CN¥135.56 Million 7.55%
Other Components CN¥1.95 Billion 108.77%
Total Equity CN¥1.80 Billion 100.00%

Shenzhen Neptunus Bioengineering Co Ltd Competitors by Market Cap

The table below lists competitors of Shenzhen Neptunus Bioengineering Co Ltd ranked by their market capitalization.

Company Market Cap
The Monarch Cement Company
PINK:MCEM
 		$616.15 Million
Yantai Eddie Precision Mach
SHG:603638
 		$616.16 Million
Komax Holding AG
PINK:KMAAF
 		$616.21 Million
Alaris Equity Partners Income Trust
TO:AD-UN
 		$616.42 Million
Beijing Kingee Culture Development Co Ltd
SHE:002721
 		$615.93 Million
Alignvest Acquisition II Corp
TO:SFC
 		$615.71 Million
VESTJYSK BANK NAM. DK 1
F:24V
 		$615.63 Million
Jiangsu Jiuding New Material Co Ltd
SHE:002201
 		$615.50 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shenzhen Neptunus Bioengineering Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 3,002,922,640 to 1,795,232,448, a change of -1,207,690,192 (-40.2%).
  • Net loss of 1,193,414,955 reduced equity.
  • Dividend payments of 506,639,806 reduced retained earnings.
  • Other comprehensive income increased equity by 410,674,355.
  • Other factors increased equity by 81,690,214.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥-1.19 Billion -66.48%
Dividends Paid CN¥506.64 Million -28.22%
Other Comprehensive Income CN¥410.67 Million +22.88%
Other Changes CN¥81.69 Million +4.55%
Total Change CN¥- -40.22%

Book Value vs Market Value Analysis

This analysis compares Shenzhen Neptunus Bioengineering Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.76x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 96.88x to 4.76x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1995-12-31 CN¥0.03 CN¥3.25 x
1996-12-31 CN¥0.04 CN¥3.25 x
1997-12-31 CN¥0.04 CN¥3.25 x
1998-12-31 CN¥0.11 CN¥3.25 x
1999-12-31 CN¥0.13 CN¥3.25 x
2000-12-31 CN¥0.15 CN¥3.25 x
2001-12-31 CN¥1.08 CN¥3.25 x
2002-12-31 CN¥0.77 CN¥3.25 x
2003-12-31 CN¥0.65 CN¥3.25 x
2004-12-31 CN¥0.64 CN¥3.25 x
2005-12-31 CN¥0.32 CN¥3.25 x
2006-12-31 CN¥0.46 CN¥3.25 x
2007-12-31 CN¥0.46 CN¥3.25 x
2008-12-31 CN¥0.43 CN¥3.25 x
2009-12-31 CN¥0.39 CN¥3.25 x
2010-12-31 CN¥0.45 CN¥3.25 x
2011-12-31 CN¥0.49 CN¥3.25 x
2012-12-31 CN¥0.52 CN¥3.25 x
2013-12-31 CN¥0.86 CN¥3.25 x
2014-12-31 CN¥0.79 CN¥3.25 x
2015-12-31 CN¥0.99 CN¥3.25 x
2016-12-31 CN¥2.41 CN¥3.25 x
2017-12-31 CN¥2.08 CN¥3.25 x
2018-12-31 CN¥2.26 CN¥3.25 x
2019-12-31 CN¥2.36 CN¥3.25 x
2020-12-31 CN¥2.23 CN¥3.25 x
2021-12-31 CN¥2.21 CN¥3.25 x
2022-12-31 CN¥1.78 CN¥3.25 x
2023-12-31 CN¥1.14 CN¥3.25 x
2024-12-31 CN¥0.68 CN¥3.25 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shenzhen Neptunus Bioengineering Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -66.48%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -3.94%
  • • Asset Turnover: 1.05x
  • • Equity Multiplier: 16.04x
  • Recent ROE (-66.48%) is below the historical average (-0.20%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1995 21.94% 22.82% 0.60x 1.59x CN¥6.19 Million
1996 31.19% 21.85% 0.63x 2.26x CN¥11.55 Million
1997 31.69% 28.97% 0.43x 2.54x CN¥12.43 Million
1998 14.83% 40.56% 0.28x 1.30x CN¥8.52 Million
1999 15.17% 35.15% 0.14x 3.14x CN¥10.59 Million
2000 26.11% 30.92% 0.23x 3.70x CN¥37.96 Million
2001 4.79% 10.43% 0.25x 1.83x CN¥-86.83 Million
2002 2.50% 5.09% 0.24x 2.03x CN¥-126.79 Million
2003 -15.60% -17.16% 0.32x 2.86x CN¥-360.99 Million
2004 1.58% 0.95% 0.62x 2.67x CN¥-117.57 Million
2005 -107.62% -27.91% 0.67x 5.78x CN¥-810.82 Million
2006 5.93% 1.58% 0.76x 4.92x CN¥-29.16 Million
2007 5.17% 1.55% 0.80x 4.17x CN¥-36.11 Million
2008 3.46% 1.10% 0.80x 3.95x CN¥-46.02 Million
2009 2.25% 0.52% 0.86x 5.03x CN¥-48.79 Million
2010 6.29% 1.17% 0.96x 5.59x CN¥-27.50 Million
2011 6.63% 0.99% 1.10x 6.11x CN¥-26.65 Million
2012 7.00% 0.92% 1.09x 6.95x CN¥-25.27 Million
2013 7.69% 1.46% 1.00x 5.27x CN¥-35.19 Million
2014 1.65% 0.24% 1.02x 6.70x CN¥-120.00 Million
2015 26.31% 4.27% 0.87x 7.07x CN¥294.29 Million
2016 7.80% 3.08% 0.82x 3.10x CN¥-118.21 Million
2017 11.59% 2.56% 0.81x 5.59x CN¥87.47 Million
2018 7.49% 1.17% 0.93x 6.87x CN¥-150.09 Million
2019 8.23% 1.24% 1.01x 6.58x CN¥-110.72 Million
2020 -0.70% -0.10% 1.01x 6.76x CN¥-629.17 Million
2021 4.43% 0.63% 1.09x 6.46x CN¥-324.35 Million
2022 -21.15% -2.62% 1.04x 7.73x CN¥-1.46 Billion
2023 -56.28% -4.64% 1.13x 10.76x CN¥-1.99 Billion
2024 -66.48% -3.94% 1.05x 16.04x CN¥-1.37 Billion

Industry Comparison

This section compares Shenzhen Neptunus Bioengineering Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $1,641,101,016
  • Average return on equity (ROE) among peers: -1.35%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Shenzhen Neptunus Bioengineering Co Ltd (000078) CN¥2.85 Billion 21.94% 8.59x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million